Latest external collaboration on country level. Dive into details by clicking on the dots.
Dive into the research topics where Michela Magnoli is active.
Featured researches published by Michela Magnoli.
European Journal of Clinical Investigation | 2017
Pietro Caironi; Serge Masson; Tommaso Mauri; Barbara Bottazzi; Roberto Leone; Michela Magnoli; Simona Barlera; Filippo Mamprin; Andrea Fedele; Alberto Mantovani; Gianni Tognoni; Antonio Pesenti; Luciano Gattinoni; Roberto Latini
The long pentraxin PTX3 is a key component of the humoral arm of innate immunity related to sepsis severity and mortality. We evaluated the clinical and prognostic significance of circulating PTX3 in the largest cohort ever reported of patients with severe sepsis or septic shock.
European Journal of Heart Failure | 2018
Franco Cosmi; Li Shen; Michela Magnoli; William T. Abraham; Inder S. Anand; John G.F. Cleland; Jay N. Cohn; Deborah Cosmi; Giorgia De Berardis; Kenneth Dickstein; Maria Grazia Franzosi; Lars Gullestad; Pardeep S. Jhund; John Kjekshus; Lars Køber; Vito Lepore; Giuseppe Lucisano; Aldo P. Maggioni; Serge Masson; John J.V. McMurray; Antonio Nicolucci; Vito Petrarolo; Fabio Robusto; Lidia Staszewsky; Luigi Tavazzi; Roberto Teli; Gianni Tognoni; John Wikstrand; Roberto Latini
Up to one‐third of patients with diabetes mellitus and heart failure (HF) are treated with insulin. As insulin causes sodium retention and hypoglycaemia, its use might be associated with worse outcomes.
European Journal of Heart Failure | 2018
Serge Masson; Sandor Batkai; Julia Beermann; Christian Bär; Angelika Pfanne; Sabrina Thum; Michela Magnoli; Giovanna Balconi; Gian Luigi Nicolosi; Luigi Tavazzi; Roberto Latini; Thomas Thum
Non‐coding microRNAs (miRNAs) are critically involved in cardiovascular pathophysiology. Since they are measurable in most body fluids, they have been proposed as circulating biomarkers. We examined the prognostic value of a specific candidate miRNA in a large cohort of patients with chronic heart failure (HF) enrolled in a multicentre clinical trial.
Circulation | 2018
Alberto Aimo; James L. Januzzi; Giuseppe Vergaro; Andrea Ripoli; Roberto Latini; Serge Masson; Michela Magnoli; Inder S. Anand; Jay N. Cohn; Luigi Tavazzi; Gianni Tognoni; Jørgen Gravning; Thor Ueland; Ståle H. Nymo; Hans-Peter Brunner-La Rocca; Antoni Bayes Genis; Josep Lupón; Rudolf A. de Boer; Akiomi Yoshihisa; Yasuchika Takeishi; Michael Egstrup; Ida Gustafsson; Hanna K. Gaggin; Kai M. Eggers; Kurt Huber; Ioannis Tentzeris; Wai H.W. Tang; Justin L. Grodin; Claudio Passino; Michele Emdin
Background: Most patients with chronic heart failure have detectable troponin concentrations when evaluated by high-sensitivity assays. The prognostic relevance of this finding has not been clearly established so far. We aimed to assess high-sensitivity troponin assay for risk stratification in chronic heart failure through a meta-analysis approach. Methods: Medline, EMBASE, Cochrane Library, and Scopus were searched in April 2017 by 2 independent authors. The terms were “troponin” AND “heart failure” OR “cardiac failure” OR “cardiac dysfunction” OR “cardiac insufficiency” OR “left ventricular dysfunction.” Inclusion criteria were English language, clinical stability, use of a high-sensitivity troponin assay, follow-up studies, and availability of individual patient data after request to authors. Data retrieved from articles and provided by authors were used in agreement with the PRISMA statement. The end points were all-cause death, cardiovascular death, and hospitalization for cardiovascular cause. Results: Ten studies were included, reporting data on 11 cohorts and 9289 patients (age 66±12 years, 77% men, 60% ischemic heart failure, 85% with left ventricular ejection fraction <40%). High-sensitivity troponin T data were available for all patients, whereas only 209 patients also had high-sensitivity troponin I assayed. When added to a prognostic model including established risk markers (sex, age, ischemic versus nonischemic etiology, left ventricular ejection fraction, estimated glomerular filtration rate, and N-terminal fraction of pro-B-type natriuretic peptide), high-sensitivity troponin T remained independently associated with all-cause mortality (hazard ratio, 1.48; 95% confidence interval, 1.41–1.55), cardiovascular mortality (hazard ratio, 1.40; 95% confidence interval, 1.33–1.48), and cardiovascular hospitalization (hazard ratio, 1.42; 95% confidence interval, 1.36–1.49), over a median 2.4-year follow-up (all P<0.001). High-sensitivity troponin T significantly improved risk prediction when added to a prognostic model including the variables above. It also displayed an independent prognostic value for all outcomes in almost all population subgroups. The area under the curve–derived 18 ng/L cutoff yielded independent prognostic value for the 3 end points in both men and women, patients with either ischemic or nonischemic etiology, and across categories of renal dysfunction. Conclusions: In chronic heart failure, high-sensitivity troponin T is a strong and independent predictor of all-cause and cardiovascular mortality, and of hospitalization for cardiovascular causes, as well. This biomarker then represents an additional tool for prognostic stratification.
International Journal of Cardiology | 2016
Serge Masson; Simona Barlera; Francesco Colotta; Michela Magnoli; Fabrizio Bonelli; Milena Moro; Roberto Marchioli; Luigi Tavazzi; Gianni Tognoni; Roberto Latini
BACKGROUND Dysregulation of the vitamin D system promotes renal dysfunction and has direct detrimental effects on the heart. Progressive deterioration of renal function is common in patients with chronic heart failure (HF) and is invariably associated with unfavorable outcomes which can be improved by early identification and timely interventions. We examined the relation between two plasma markers of vitamin D metabolism and worsening of renal function (WRF) in a large cohort of patients with chronic HF. METHODS Plasma levels of 1,25-dihydroxyvitamin D (1,25(OH)2D) and parathyroid hormone PTH (1-84) were measured in 1237 patients with clinical evidence of chronic and stable HF enrolled in the multicentre GISSI-HF trial and followed for 3.9years. We examined the relation of 1,25(OH)2D, PTH(1-84), and their ratio with WRF, defined as first increase in serum creatinine concentration ≥0.3mg/dL and ≥25% at two consecutive measurements at any time during the study. RESULTS Lower 1,25(OH)2D/PTH(1-84) ratio was associated with a higher baseline serum concentration of creatinine, winter season, female sex and older age; 335 patients (29.6%) experienced an episode of WRF. After adjustment, a lower 1,25(OH)2D/PTH(1-84) ratio remained significantly associated with a higher risk of WRF (HR=0.75 [0.62-0.90], p=0.002) and correctly reclassified events. This ratio also independently predicted mortality and admission to hospital for cardiovascular reasons. CONCLUSIONS The plasma 1,25(OH)2D/PTH(1-84) ratio is a promising indicator of future risk of deterioration of renal function in patients with chronic HF and mild renal impairment, that may serve to optimize therapies and improve outcomes.
International Journal of Cardiology | 2018
Alberto Aimo; James L. Januzzi; Giuseppe Vergaro; Andrea Ripoli; Roberto Latini; Serge Masson; Michela Magnoli; Inder S. Anand; Jay N. Cohn; Luigi Tavazzi; Gianni Tognoni; Jørgen Gravning; Thor Ueland; Ståle H. Nymo; Hans-Peter Brunner-La Rocca; Antoni Bayes-Genis; Josep Lupón; Rudolf A. de Boer; Akiomi Yoshihisa; Yasuchika Takeishi; Michael Egstrup; Ida Gustafsson; Hanna K. Gaggin; Kai M. Eggers; Kurt Huber; Ioannis Tentzeris; W.H. Wilson Tang; Justin L. Grodin; Claudio Passino; Michele Emdin
BACKGROUND In a recent individual patient data meta-analysis, high-sensitivity troponin T (hs-TnT) emerged as robust predictor of prognosis in stable chronic heart failure (HF). In the same population, we compared the relative predictive performances of hs-TnT, N-terminal fraction of pro-B-type natriuretic peptide (NT-proBNP), hs-C-reactive protein (hs-CRP), and estimated glomerular filtration rate (eGFR) for prognosis. METHODS AND RESULTS 9289 patients (66 ± 12 years, 77% men, 85% LVEF <40%, 60% ischemic HF) were evaluated over a 2.4-year median follow-up. Median eGFR was 58 mL/min/1.73 m2 (interquartile interval 46-70; n = 9220), hs-TnT 16 ng/L (8-20; n = 9289), NT-proBNP 1067 ng/L (433-2470; n = 8845), and hs-CRP 3.3 mg/L (1.4-7.8; n = 7083). In a model including all 3 biomarkers, only hs-TnT and NT-proBNP were independent predictors of all-cause and cardiovascular mortality and cardiovascular hospitalization. hs-TnT was a stronger predictor than NT-proBNP: for example, the risk for all-cause death increased by 54% per doubling of hs-TnT vs. 24% per doubling of NT-proBNP. eGFR showed independent prognostic value from both hs-TnT and NT-proBNP. The best hs-TnT and NT-proBNP cut-offs for the prediction of all-cause death increased progressively with declining renal function (eGFR ≥ 90: hs-TnT 13 ng/L and NT-proBNP 825 ng/L; eGFR < 30: hs-TnT 40 ng/L and NT-proBNP 4608 ng/L). Patient categorization according to these cut-offs effectively stratified patient prognosis across all eGFR classes. CONCLUSIONS hs-TnT conveys independent prognostic information from NT-proBNP, while hs-CRP does not. Concomitant assessment of eGFR may further refine risk stratification. Patient classification according to hs-TnT and NT-proBNP cut-offs specific for the eGFR classes holds prognostic significance.
Critical Care Medicine | 2017
Fabrizio Semeraro; Mario Colucci; Pietro Caironi; Serge Masson; Concetta T. Ammollo; Roberto Teli; Nicola Semeraro; Michela Magnoli; Giovanni Salati; Michele Isetta; Mauro Panigada; Tommaso Tonetti; Gianni Tognoni; Roberto Latini; Antonio Pesenti; Luciano Gattinoni
Objective: Thrombocytopenia is the most common hemostatic disorder during sepsis and is associated with high mortality. We examined whether fibrinolytic changes precede incident thrombocytopenia and predict outcome in patients with severe sepsis. Design: Nested study from the multicenter, randomized, controlled trial on the efficacy of albumin replacement in severe sepsis or septic shock (the Albumin Italian Outcome Sepsis trial). Setting: Forty ICUs in Italy. Patients: Three groups of patients were selected: 1) patients with platelet count less than or equal to 50 × 109/L at study entry (n = 85); 2) patients with baseline platelet count greater than or equal to 100 × 109/L who developed thrombocytopenia (⩽ 50 × 109/L) within 28 days (n = 100); 3) patients with platelet count always more than or equal to 100 × 109/L (n = 95). Interventions: Fibrinolytic variables, including fibrinolysis inhibitors and in vivo markers of plasmin generation, were measured on day 1. Measurements and Main Results: Patients with early thrombocytopenia (group 1) and those who developed it later (group 2) had similar illness severity and 90-day mortality, whereas patients without thrombocytopenia (group 3) had milder disease and lower mortality. Fibrinolysis was markedly (and similarly) depressed in groups 1 and 2 as compared with group 3. Major fibrinolytic changes included increased levels of plasminogen activator inhibitor 1 and extensive activation/consumption of thrombin activatable fibrinolysis inhibitor. Most fibrinolytic variables were significantly associated with mortality in univariate models. However, only thrombin activatable fibrinolysis inhibitor level and in vivo markers of fibrinolysis activation, namely plasmin-antiplasmin complex, and D-dimer, were independently associated with mortality after adjustment for Simplified Acute Physiology Score-II score, sex, and platelet count. Furthermore, the coexistence of impaired fibrinolysis and low platelets was associated with an even greater mortality. Conclusions: Impaired fibrinolysis, mainly driven by plasminogen activator inhibitor-1 increase and thrombin activatable fibrinolysis inhibitor activation, is an early manifestation of sepsis and may precede the development of thrombocytopenia. Thrombin activatable fibrinolysis inhibitor level, in particular, proved to be an independent predictor of mortality, which may improve risk stratification of patients with severe sepsis.
Critical Care | 2016
Giuseppe Ristagno; Serge Masson; Marjaana Tiainen; Stepani Bendel; Roberto Bernasconi; Tero Varpula; Valentina Milani; Jukka Vaahersalo; Michela Magnoli; Eberhard Spanuth; Simona Barlera; Roberto Latini; Sanna Hoppu; Ville Pettilä; Markus B. Skrifvars
European Heart Journal | 2018
Deborah Cosmi; Li Shen; Michela Magnoli; W T Abrahm; Inder S. Anand; John G.F. Cleland; Jay N. Cohn; G De Berardis; Aldo P. Maggioni; Serge Masson; Antonio Nicolucci; Lidia Staszewsky; Gianni Tognoni; Franco Cosmi; Roberto Latini
Critical Care Medicine | 2018
Helge Røsjø; Serge Masson; Pietro Caironi; Mats Stridsberg; Michela Magnoli; Geir Christensen; Gabriella Moise; Maria Cristina Urbano; Luciano Gattinoni; Antonio Pesenti; Roberto Latini; Torbjørn Omland